A Phase 1/2 Single-Dose Study of TAK-662 in Japanese Patients with Congenital Protein C Deficiency
This study is for Japanese participants with congenital protein C deficiency. The main aim of this study is to check how much TAK-662 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give patients in the future.~Participants will receive 1 single infusion of TAK-662.~They will stay at the clinic until 3 days after the infusion. Then, participants will return to their clinic 7days after the infusion to check side effect from the study treatment.